Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms

Pentostatin (2'-deoxycoformycin, DCF) was administered to 17 patients with a variety of lymphoid neoplasms, both T- and B-cell, that were refractory to conventional treatments. Several responses and 2 complete remissions occurred. Toxic effects were less severe than previously described: this m...

Full description

Saved in:
Bibliographic Details
Published inScandinavian journal of haematology Vol. 32; no. 2; p. 130
Main Authors Spiers, A S, Ruckdeschel, J C, Horton, J
Format Journal Article
LanguageEnglish
Published Denmark 01.02.1984
Subjects
Adult
Coformycin - analogs & derivatives
Coformycin - therapeutic use
Coformycin - toxicity
Female
Herpes Zoster - etiology
Humans
Keratitis - chemically induced
Lymphoma - drug therapy
Male
Pentostatin
Ribonucleosides - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Pentostatin (2'-deoxycoformycin, DCF) was administered to 17 patients with a variety of lymphoid neoplasms, both T- and B-cell, that were refractory to conventional treatments. Several responses and 2 complete remissions occurred. Toxic effects were less severe than previously described: this may be attributable to relatively low doses of DCF or to precautions taken to prevent tumour lysis syndrome. DCF appears valuable as a second-line treatment in non-Hodgkin's lymphomas and as initial treatment in T-cell chronic lymphocytic leukaemia and mycosis fungoides. Although myelosuppression is mild, immunosuppression and superinfection are potential hazards of treatment with DCF. The ocular toxicity of DCF, previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study.
ISSN:0036-553X
DOI:10.1111/j.1600-0609.1984.tb02167.x